Hemorrhoid Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Suppository, Sprays, Creams & Ointments, Others), By Application (Hospital Pharmacy, Drug Stores & Retail Pharmacy, Online Pharmacy), Regional Insights and Forecast from 2026 to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

HEMORRHOID TREATMENT MARKET OVERVIEW

The global Hemorrhoid Treatment Market size estimated at USD 1.13 billion in 2026 and is projected to reach USD 2 billion by 2035, growing at a CAGR of 6.51% from 2026 to 2035.

The Hemorrhoid Treatment Market is expanding steadily due to the increasing prevalence of anorectal disorders, aging populations, sedentary lifestyles, and dietary changes. More than 50% of adults experience hemorrhoid symptoms by the age of 50, creating sustained demand for pharmaceutical and minimally invasive treatment options. Over 78% of diagnosed patients initially receive conservative medication before surgical intervention, while nearly 22% require procedural treatment because of advanced disease severity. Prescription creams, ointments, suppositories, and office-based procedures account for a significant portion of clinical management. Improved diagnosis, greater awareness campaigns, and the availability of non-invasive therapies continue to strengthen the Hemorrhoid Treatment Market across hospitals, specialty clinics, and retail pharmacies.

The United States represents one of the largest contributors to the Hemorrhoid Treatment Market due to its high incidence of digestive disorders and obesity. Approximately 10 million Americans experience hemorrhoids annually, while nearly 75% of adults are expected to develop hemorrhoids during their lifetime. More than 63% of diagnosed patients prefer non-surgical therapies, and approximately 28% undergo minimally invasive procedures such as rubber band ligation or infrared coagulation. Hospital outpatient centers perform over 1 million anorectal procedures annually, supporting continuous demand for advanced treatment products, prescription medications, and specialized surgical devices throughout the country.

KEY FINDINGS

LATEST TRENDS

The Hemorrhoid Treatment Market is witnessing significant transformation because healthcare providers increasingly recommend minimally invasive treatment options and advanced pharmaceutical formulations. Clinical evidence indicates that almost 82% of Grade I and Grade II hemorrhoid patients respond effectively to conservative therapies, reducing the need for surgery. Topical creams, corticosteroid formulations, suppositories, and anesthetic preparations continue to dominate prescriptions due to their rapid symptom relief. Digital healthcare consultations have also increased patient accessibility, with online medical consultations for anorectal disorders rising by approximately 36% over the past few years. Furthermore, herbal and plant-derived formulations now account for nearly 18% of newly introduced hemorrhoid care products, reflecting consumer preference for natural ingredients.

Technological innovation has also improved procedural treatment. Rubber band ligation remains the preferred office-based intervention, accounting for nearly 46% of minimally invasive procedures worldwide. Infrared coagulation contributes approximately 19%, while sclerotherapy represents nearly 17% of procedural interventions. Disposable surgical instruments have witnessed greater adoption because hospitals prioritize infection prevention and operational efficiency. More than 71% of colorectal surgeons now utilize advanced disposable procedural kits. Patient awareness campaigns have increased screening participation by approximately 23%, supporting earlier diagnosis and improved treatment outcomes.

MARKET DYNAMICS

Driver

Rising prevalence of sedentary lifestyles and digestive disorders.

The growing incidence of obesity, chronic constipation, pregnancy-related hemorrhoids, and sedentary work environments remains the strongest growth driver for the Hemorrhoid Treatment Market. More than 58% of adults spend over 8 hours daily sitting, increasing the likelihood of anorectal disorders. Clinical studies indicate that approximately 65% of hemorrhoid patients have a history of chronic constipation, while obesity contributes to nearly 37% of diagnosed cases. Aging populations further strengthen market demand because nearly 54% of patients receiving hemorrhoid treatment are older than 45 years.

Restraint

Patient reluctance toward clinical consultation.

Despite increasing disease prevalence, delayed diagnosis remains a major challenge. Nearly 44% of individuals experiencing hemorrhoid symptoms postpone seeking professional care due to embarrassment. Approximately 39% depend exclusively on self-medication without physician supervision, while almost 27% discontinue prescribed therapy once symptoms temporarily improve. Rural healthcare accessibility also limits treatment availability, with specialized colorectal services available to only 36% of patients living outside major urban centers.

Expansion of minimally invasive treatment technologies

Opportunity

Demand for outpatient hemorrhoid management continues to increase because patients seek procedures requiring shorter recovery periods. Nearly 62% of physicians now recommend office-based interventions before considering surgery. Rubber band ligation demonstrates clinical success rates exceeding 85%, while infrared coagulation achieves symptom improvement in approximately 79% of treated patients.

Hospitals continue investing in disposable surgical instruments, advanced anoscopes, and energy-based treatment technologies to improve procedural efficiency.

Recurrence of hemorrhoid disease after treatment

Challenge

One of the most persistent clinical challenges involves disease recurrence following conservative treatment. Approximately 32% of patients experience symptom recurrence within several years if dietary and lifestyle modifications are not maintained. Nearly 48% of recurrent cases require repeated pharmaceutical therapy, while 19% eventually undergo procedural intervention.

Physician adherence to standardized treatment protocols varies across healthcare systems, creating differences in patient outcomes. Limited patient compliance with fiber-rich diets affects nearly 53% of diagnosed individuals, increasing recurrence risk.

•   
•   
  

  Download Free Sample to learn more about this report

    

HEMORRHOID TREATMENT MARKET SEGMENTATION

By Type

• Suppository: Suppositories remain an important segment of the Hemorrhoid Treatment Market because they deliver medication directly to the affected anorectal tissues and provide effective relief for internal hemorrhoids. This segment accounts for approximately 24% of the global market share by product type. Clinical observations indicate that nearly 69% of patients with Grade I and Grade II internal hemorrhoids experience symptom improvement within 7 days when suppositories are used according to prescribed treatment schedules. More than 61% of gastroenterologists recommend suppositories for patients presenting with rectal bleeding, inflammation, and discomfort associated with internal hemorrhoids.

• Sprays: Sprays represent a growing category in the Hemorrhoid Treatment Market because they provide hygienic application and minimize physical contact with inflamed tissue. This segment contributes approximately 11% of the total market share. Nearly 54% of patients choosing spray formulations cite ease of application as the primary reason for product selection. Cooling sprays containing local anesthetics and anti-inflammatory ingredients demonstrate symptom relief within 15 minutes for nearly 73% of users. Healthcare professionals increasingly recommend spray formulations following minimally invasive hemorrhoid procedures, with approximately 37% of post-procedure patients receiving spray-based therapies for pain management.

• Creams & Ointments: Creams and ointments dominate the Hemorrhoid Treatment Market with approximately 49% market share, making them the largest product segment. Their widespread adoption is supported by rapid symptom relief, affordability, and broad availability through hospital pharmacies, retail pharmacies, and online platforms. More than 76% of newly diagnosed hemorrhoid patients receive topical creams or ointments as first-line therapy. Products containing corticosteroids, lidocaine, zinc oxide, or herbal extracts account for nearly 68% of total topical prescriptions.

• Others: The "Others" category includes medicated wipes, gels, foams, herbal preparations, oral medications, and advanced procedural products. This segment represents approximately 16% of the Hemorrhoid Treatment Market. Medicated wipes account for nearly 34% of this category due to increasing emphasis on hygiene during hemorrhoid management. Oral flavonoid-based therapies contribute approximately 27%, while foam-based products represent nearly 18% because of improved patient comfort during application. Herbal preparations continue gaining popularity, particularly in Asia-Pacific, where they account for approximately 29% of non-prescription hemorrhoid treatment products.

By Application

• Hospital Pharmacy: Hospital pharmacies hold the leading position in the Hemorrhoid Treatment Market, accounting for approximately 41% of global distribution. Their dominance is supported by physician-directed prescribing practices and increasing outpatient treatment volumes. More than 74% of patients undergoing minimally invasive hemorrhoid procedures receive medications directly through hospital pharmacies. Prescription creams, corticosteroid suppositories, local anesthetics, antibiotics, and post-operative care products constitute nearly 82% of hospital pharmacy dispensing.

• Drug Stores & Retail Pharmacy: Drug stores and retail pharmacies account for approximately 38% of the Hemorrhoid Treatment Market, making them the second-largest distribution channel. Nearly 72% of patients with mild hemorrhoid symptoms purchase over-the-counter products before seeking physician consultation. Topical creams, ointments, medicated wipes, and suppositories represent approximately 79% of retail pharmacy sales within this therapeutic category. Pharmacist recommendations influence purchasing decisions for nearly 57% of first-time consumers.

• Online Pharmacy: Online pharmacies represent approximately 21% of the Hemorrhoid Treatment Market and continue recording strong adoption because of privacy, convenience, and home delivery services. Nearly 48% of younger adults prefer purchasing hemorrhoid medications through digital pharmacy platforms to avoid in-person consultations. Online prescription fulfillment has increased by approximately 34%, while same-day delivery services are now available to nearly 43% of urban consumers. Topical medications account for approximately 66% of online hemorrhoid product sales, followed by suppositories at 19% and oral therapies at 15%.

•   
•   
  Download Free Sample to learn more about this report

    

HEMORRHOID TREATMENT MARKET REGIONAL INSIGHTS

• North America

North America accounts for 32% of the global hemorrhoid treatment market, supported by increasing awareness of digestive health, rising adoption of minimally invasive procedures, and growing demand for advanced treatment options. The United States represents the largest regional contributor due to a well-established healthcare infrastructure, higher access to specialized colorectal care, and increasing use of prescription medications, topical therapies, and surgical procedures. The growing prevalence of sedentary lifestyles, obesity, and dietary-related digestive disorders is contributing to higher demand for hemorrhoid management solutions. Healthcare providers are also adopting advanced technologies to improve treatment outcomes and patient comfort.

• Europe

Europe holds 27% of the global hemorrhoid treatment market, driven by increasing healthcare expenditure, improved diagnosis rates, and strong adoption of non-surgical treatment methods. Countries such as Germany, France, Italy, and the United Kingdom are major contributors due to their advanced healthcare systems and availability of specialized medical services. Rising awareness regarding early diagnosis and treatment of anorectal disorders is encouraging patients to seek medical attention. The region is witnessing greater demand for minimally invasive procedures, pharmaceutical treatments, and advanced clinical therapies as healthcare professionals focus on reducing recovery time and improving patient outcomes.

• Asia-Pacific

Asia-Pacific represents 26% of the global hemorrhoid treatment market, supported by a large patient population, improving healthcare accessibility, and increasing awareness about digestive health conditions. China, India, Japan, South Korea, and Southeast Asian countries are key contributors due to expanding healthcare facilities and growing availability of modern treatment options. Rising urbanization, changing dietary patterns, and increased adoption of sedentary lifestyles are contributing to the demand for hemorrhoid treatment products and procedures. Government healthcare initiatives and investments in medical infrastructure are further improving access to diagnosis and treatment across developing economies in the region.

• Middle East & Africa

Middle East & Africa contributes 7% of the global hemorrhoid treatment market, with growth supported by improving healthcare infrastructure, increasing medical awareness, and expanding access to specialized healthcare services. Gulf countries such as Saudi Arabia and the United Arab Emirates are witnessing higher adoption of advanced treatment solutions due to investments in healthcare modernization. South Africa also contributes through rising demand for pharmaceutical therapies and clinical procedures. Although awareness levels vary across countries, increasing healthcare development programs and improved diagnostic capabilities are creating new opportunities for hemorrhoid treatment providers in the region.

• Rest of World

Rest of World represents 8% of the global hemorrhoid treatment market, with Latin America contributing significantly through rising healthcare awareness and expanding medical services. Countries such as Brazil, Mexico, and Argentina are important markets due to increasing demand for pharmaceutical treatments, outpatient procedures, and minimally invasive therapies. Growing urban populations, changing lifestyles, and improved access to healthcare facilities are supporting the adoption of hemorrhoid management solutions. Healthcare investments and increasing patient awareness regarding early treatment are expected to strengthen market development across emerging economies in this region.

KEY INDUSTRY PLAYERS

The global Hemorrhoid Treatment Market consists of leading pharmaceutical companies, medical device manufacturers, and healthcare providers focused on improving treatment effectiveness, patient comfort, and minimally invasive care. Companies such as Johnson & Johnson, Pfizer, Bayer, GlaxoSmithKline, and Sanofi are strengthening their market presence through topical treatments, oral medications, and advanced therapeutic solutions. AbbVie, AstraZeneca, and Novartis are developing pharmaceutical products and healthcare solutions that support improved disease management.

Manufacturers including Cook Medical, Boston Scientific, Medtronic, and Olympus are focusing on minimally invasive devices and procedures for hemorrhoid treatment. Companies are investing in improved topical formulations, patient-friendly applicators, advanced drug delivery technologies, and minimally invasive treatment systems. The competitive landscape is driven by increasing prevalence of hemorrhoids, growing preference for non-surgical treatment, improved patient awareness, and demand for convenient and effective therapeutic solutions.

LIST OF TOP HEMORRHOID TREATMENT COMPANIES

• Pfizer
• Ranbaxy
• Himalaya
• Astra zeneca
• Glenmark pharmaceuticals
• Glaxosmithkline plc.
• SURKON MEDICAL CO.,LTD.
• Jiangsu Kangjin Medical Instrument Co.,Ltd.
• LocaMed Limited
• Reach surgical
• Ultroid
• Sklar Surgical Instruments
• Cook
• Medline Industries, Inc.

List Of Top 2 Companies Market Share

• Pfizer – Approximately 16% market share, supported by a broad pharmaceutical portfolio, extensive global distribution network, and strong physician confidence in prescription anorectal medications.

• Glaxosmithkline plc. – Approximately 12% market share, driven by established consumer healthcare products, extensive pharmacy presence, and consistent demand for topical hemorrhoid treatment formulations.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity in the Hemorrhoid Treatment Market continues to increase as pharmaceutical manufacturers and medical device companies focus on minimally invasive technologies, advanced topical formulations, and digital healthcare integration. Approximately 64% of new investments are directed toward research and development of pharmaceutical products, while 23% support minimally invasive procedural devices and 13% are allocated to manufacturing expansion and supply chain modernization. More than 58% of investment projects prioritize improving patient comfort through preservative-free creams, extended-release suppositories, and combination therapies containing anti-inflammatory and anesthetic agents.

Hospital infrastructure modernization is creating additional opportunities for manufacturers supplying disposable surgical instruments, ligation systems, and infrared coagulation devices. Nearly 72% of tertiary hospitals have expanded outpatient colorectal services, increasing demand for specialized treatment equipment. Digital health platforms are also attracting investment, with online prescription management growing by approximately 34% and telemedicine consultations for anorectal disorders increasing by 31%. Emerging economies continue presenting attractive expansion opportunities because healthcare insurance coverage has improved significantly and physician awareness programs have increased early diagnosis rates by approximately 26%.

NEW PRODUCT DEVELOPMENT

Product innovation remains a major strategic priority within the Hemorrhoid Treatment Market as manufacturers focus on improving therapeutic effectiveness, patient convenience, and treatment compliance. Approximately 61% of newly introduced products feature multi-action formulations combining anti-inflammatory, analgesic, and protective ingredients within a single treatment. Advanced topical creams containing improved absorption technology have demonstrated symptom relief within 5 days for nearly 79% of patients during routine clinical use. Suppositories with prolonged-release formulations now account for approximately 18% of new pharmaceutical launches, reducing application frequency and improving patient adherence.

Medical device innovation is progressing rapidly through the development of disposable rubber band ligation systems, precision anoscopes, and improved infrared coagulation devices. Nearly 47% of new procedural products emphasize reduced operating time and improved patient safety. Spray-based treatments with touch-free applicators continue gaining popularity, representing approximately 14% of recent product introductions because they improve hygiene and patient comfort. Herbal formulations containing botanical extracts have expanded significantly and now constitute approximately 21% of newly launched over-the-counter hemorrhoid products.

RECENT DEVELOPMENTS

• January 2025: Medline Industries, Inc. expanded advanced surgical product and healthcare supply capabilities. Medline Industries, Inc. introduced upgraded medical-surgical solutions by improving product availability, supply chain automation, and healthcare distribution technologies to support hospitals with efficient surgical inventory management and clinical operations.
• March 2025: AstraZeneca strengthened innovation programs for advanced healthcare solutions. AstraZeneca expanded research initiatives by advancing technology-driven healthcare development, improving therapeutic platforms, and supporting next-generation medical solutions through enhanced research capabilities and strategic innovation programs.
• July 2025: GlaxoSmithKline plc. Advanced specialty healthcare development initiatives. GlaxoSmithKline plc. progressed its healthcare portfolio by strengthening research capabilities, improving product development pipelines, and integrating advanced scientific technologies to address evolving medical treatment requirements.
• February 2026: Pfizer expanded its medical innovation pipeline through advanced healthcare programs. Pfizer advanced multiple research and development programs by introducing new product enhancements, strengthening clinical development activities, and improving technology-driven healthcare solutions across therapeutic categories.
• May 2026: Cook Medical enhanced minimally invasive surgical technology offerings. Cook Medical expanded surgical solutions by improving minimally invasive procedure products, advancing device engineering capabilities, and supporting healthcare professionals with enhanced procedural efficiency and patient care technologies.

HEMORRHOID TREATMENT MARKET REPORT COVERAGE

The Hemorrhoid Treatment Market report provides comprehensive analysis covering pharmaceutical products, minimally invasive treatment technologies, distribution channels, regional performance, competitive landscape, and emerging investment opportunities. The report evaluates major product categories including suppositories, sprays, creams & ointments, and other therapeutic solutions while analyzing their respective market shares and clinical adoption trends. It also examines key application segments consisting of hospital pharmacies, drug stores & retail pharmacies, and online pharmacies, supported by relevant statistical insights and market performance indicators.

The study further assesses regional developments across North America, Europe, Asia-Pacific, and the Middle East & Africa, highlighting healthcare infrastructure, treatment accessibility, patient demographics, and pharmaceutical utilization patterns. Competitive profiling includes major international pharmaceutical companies, medical device manufacturers, and specialized colorectal treatment providers operating within the Hemorrhoid Treatment Market. Additionally, the report evaluates innovation trends, investment priorities, product development activities, and recent manufacturer initiatives undertaken between 2023 and 2025.